Tvardi Therapeutics, Inc. (TVRD) Stock Price, Financials & Summary

Price chart

Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18

Key dataSep 18, 2026

Open$1.63

From 52W high−96.21%

Volume121528.00

Market cap$21.74M

P/E (TTM)—

P/S (TTM)—

Div yield—

Key dataSep 18, 2026

Open

$1.63

From 52W high

−96.21%

Volume

121528.00

Market cap

$21.74M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−0.2x

P/E (TTM)

—

RSI (14)

35.4

MomentumView details →

1D Return

+0.62%

YTD Return

−61.90%

SummaryUpdated Jun 1, 2026

Tvardi Therapeutics, Inc. (NASDAQ:TVRD) is a clinical-stage biopharmaceutical company founded to develop innovative oral therapies for fibrosis-driven diseases. The company went public in April 2025 and focuses specifically on targeting the STAT3 pathway, a critical cellular signaling mechanism involved in inflammation and tissue scarring. Tvardi's approach centers on developing small molecule drugs that can be taken orally, offering potential advantages over injectable treatments commonly used in serious fibrotic conditions.

Ask drillr about Tvardi Therapeutics, Inc. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−0.2x

EV/Sales

—

P/S (TTM)

—

P/B (TTM)

2.6x

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−310.94%

ROA (TTM)

−148.79%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

−100.00%

EPS YoY

+78.93%

FCF YoY

+27.62%

Revenue CAGR 3Y

−100.00%

EPS CAGR 3Y

+94.72%

EBITDA YoY

−37.55%

MomentumView details →

1D Return

+0.62%

YTD Return

−61.90%

1Y Return

−95.72%

RSI (14)

35.4

vs 50D SMA

−22.85%

vs 200D SMA

−49.19%

Capital & dividendView details →

Debt/Equity

0.02x

Current Ratio

1.87x

Quick Ratio

1.87x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.69

EPS Surprise

2.05%

Beats (12Q)

2/12

Next Q EPS Est

−$0.55

Avg Surprise (4Q)

−5.79%

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

−26.06M

Op. CF (TTM)

−25.03M

Next earningsNov 12, 2026 →

Latest newsMore news →

Tvardi Therapeutics reported a net loss of $6.5 million for Q2 2026, compared with net income of $4.2 million in Q2 2025, with research and development expenses of $4.0 million and general and administrative expenses of $2.6 million.38d ago

Similar companies

Tharimmune, Inc.THAR Atossa Therapeutics, Inc.ATOS GridAI Technologies Corp.GRDX TScan Therapeutics, Inc.TCRX Cellectar Biosciences, Inc.CLRB Jasper Therapeutics, Inc.JSPR Find similar companies →

Latest newsMore news →